IFNB1 and cancer: The results from comparative oncology studies testing VSV therapy in dogs with naturally occurring cancer became part of the IND safety packet that was successfully approved by the FDA leading to launch of a first-in-human (FIH) VSV-IFNβ-NIS dose escalation study that followed a standard 3 + 3 design.